{'fraction_non_alphanumeric': 0.03054989816700611, 'fraction_numerical': 0.0, 'mean_word_length': 5.929577464788732, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Phase II study of paclitaxel and vinorelbine (Pacl‐Vin) in hormone‐refractory metastatic prostate cancer: double tubulin targeting

Background: Androgen ablation is the standard treatment for advanced prostate cancer. However, most patients will eventually develop progressive hormone‐refractory prostate cancer (HRPC). The aim of the Pacl‐Vin study was to determine the efficacy and safety of paclitaxel in combination with vinorelbine in patients with HRPC, following from a phase I trial.